Biotechnology is used in medicine to understand disease, prevent illness, diagnose conditions, produce therapeutic substances and develop treatments that act through biological mechanisms. Medical biotechnology encompasses recombinant DNA technology, molecular diagnostics, genomics, cell culture, monoclonal antibody technology, gene therapy, cell therapy, vaccine platforms, tissue engineering, synthetic biology and computational biological analysis. One of its earliest major achievements was the production of recombinant human insulin, in which genetically engineered microorganisms were used to produce human insulin for medical use.
Biotechnology subsequently enabled production of many proteins that are difficult or impossible to obtain efficiently from natural tissues. Modern biotechnology can also analyse DNA and RNA to identify disease associated variants, detect infectious organisms and characterise tumours. The field therefore operates across the entire medical pathway from basic research and laboratory diagnosis through pharmaceutical manufacturing and advanced therapies.
Recombinant DNA technology allows scientists to introduce a gene encoding a desired protein into a suitable host cell. The host then expresses the protein, which can be harvested and purified for therapeutic use. This approach has enabled production of insulin, growth hormones, clotting factors, cytokines and numerous other biological medicines. The choice of production system depends on the properties of the target protein.
Bacteria can grow rapidly and are relatively straightforward to culture, but they may not perform certain eukaryotic post translational modifications. Yeast can provide some eukaryotic processing, while mammalian cells are often used for complex therapeutic proteins such as monoclonal antibodies. Manufacturing requires controlled cell culture, purification, quality testing and regulatory oversight. Recombinant biotechnology has therefore transformed pharmaceutical production by providing reliable sources of molecules that previously required extraction from human or animal tissues or were difficult to obtain in sufficient quantities.
Monoclonal antibodies are another major medical biotechnology application. These are highly specific proteins designed to recognise particular molecular targets. Their therapeutic mechanisms vary. Some antibodies block signalling pathways that promote disease, others bind molecules involved in inflammation, and some target cancer associated antigens. Certain antibody based treatments can recruit immune mechanisms to destroy target cells. Antibody technology also supports diagnostic testing because antibodies can selectively bind specific proteins, hormones, pathogens or other molecules.
Monoclonal antibodies are generally produced using engineered mammalian cell lines and require extensive purification and characterisation. Their development illustrates how knowledge of molecular recognition can be converted into medicines with highly specific biological targets. However, specificity does not guarantee absence of adverse effects because target molecules may have functions in normal tissues, and immune reactions or other pharmacological effects can occur.
Vaccines use biotechnology to stimulate protective immune responses without causing the targeted disease in its usual form. Modern vaccine technologies include recombinant protein vaccines, viral vector vaccines and nucleic acid based platforms such as messenger RNA vaccines. Recombinant approaches can produce selected pathogen proteins that are purified and formulated with other components to stimulate immunity. Viral vectors can deliver genetic information encoding an antigen.
Messenger RNA vaccines deliver nucleic acid instructions that allow cells to transiently produce an antigen, after which the immune system responds to it. Biotechnology also supports vaccine development through genomic sequencing, structural biology, computational antigen design, cell culture and molecular diagnostics. The choice of platform depends on the pathogen, target antigen, required immune response, manufacturing characteristics and safety considerations. Biotechnology has consequently changed the speed and flexibility with which vaccine candidates can be designed and manufactured.
Genomic and molecular biotechnology is widely used for diagnosis and disease classification. Polymerase chain reaction can amplify selected nucleic acid sequences, allowing sensitive detection of genetic material from pathogens or patients. Sequencing can identify mutations, determine pathogen genomes and characterise tumour DNA. In inherited disease, genetic testing can identify pathogenic variants or variants that may contribute to disease risk. Cancer genomics can identify molecular alterations that help classify tumours and sometimes identify targets for specific therapies.
Pharmacogenomics investigates how genetic variation can influence responses to medicines. However, genetic findings must be interpreted carefully because not every detected variant causes disease and many variants have uncertain significance. Diagnostic biotechnology therefore requires validated assays, appropriate reference populations, quality control and clinical interpretation rather than relying solely on the ability to detect a molecular difference.
Gene therapy and cell therapy represent more direct forms of biotechnology based treatment. Gene therapy aims to modify genetic information or gene expression to treat disease. Approaches can involve delivering a functional gene, altering gene activity or editing DNA. Viral vectors are frequently investigated or used because viruses naturally possess mechanisms for entering cells, although engineered vectors are designed to reduce unwanted viral properties and deliver therapeutic genetic material.
Cell therapies involve administering living cells that have been selected, expanded, differentiated or genetically modified. Chimeric antigen receptor T cell therapy is an example in which a patient's or donor's T cells are genetically modified so that they recognise particular cancer associated targets. Such therapies can be highly specialised and require complex manufacturing, quality control and clinical monitoring. Potential risks include immune reactions, unintended biological effects and difficulties controlling the persistence or behaviour of modified cells.
Biotechnology also contributes to regenerative medicine, tissue engineering and drug discovery. Stem cells can be differentiated into specialised cells for research and, in selected contexts, therapeutic applications. Organoids can model human tissues and diseases, allowing researchers to study mechanisms and test candidate treatments. High throughput screening combines automated biological assays with computational analysis to identify compounds that interact with disease related targets. Bioinformatics can integrate genomic, transcriptomic and proteomic information to identify pathways associated with disease.
Structural biology can reveal molecular binding sites that guide drug design. Biotechnology also supports production of biosimilars, which are biological medicines highly similar to already approved reference products. These technologies can reduce development times for selected products or provide new therapeutic possibilities, although biological medicines remain technically complex and require extensive evidence demonstrating quality, safety and effectiveness.
Medical biotechnology has transformed medicine but also introduces challenges involving safety, cost, manufacturing complexity, regulation, accessibility and ethical governance. Biological medicines can be highly specific and effective, but some require injection or infusion, refrigeration or specialised manufacturing. Gene and cell therapies may involve complex personalised production processes that are substantially more difficult to manufacture than conventional tablets. Genetic testing creates important privacy and interpretation issues because genomic information can reveal information about individuals and biological relatives.
Biotechnology derived products must undergo rigorous evaluation because laboratory activity does not establish clinical effectiveness by itself. Regulatory systems therefore assess manufacturing quality, preclinical evidence and clinical trial results before approval. Overall, biotechnology provides the molecular tools and biological production systems underlying many modern medicines, from recombinant proteins and vaccines to molecular diagnostics, antibody treatments, gene therapies and engineered cells.
